<SEC-DOCUMENT>0001193125-21-271924.txt : 20211112
<SEC-HEADER>0001193125-21-271924.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20210913214614
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-21-271924
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g111280dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROPES&nbsp;&amp; GRAY LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRUDENTIAL TOWER</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 BOYLSTON STREET</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BOSTON, MA 02199-3600</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WWW.ROPESGRAY.COM</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;13, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life
Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dillon Hagius / Joe McCann &#150; Legal </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Nudrat Salik / Daniel Gordon &#150; Accounting </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MiNK Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Amendment No.&nbsp;2 to Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Submitted July&nbsp;28, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">CIK
No.&nbsp;0001840229 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of MiNK Therapeutics, Inc. (f/k/a AgenTus Therapeutics, Inc., the &#147;Company&#148;), and pursuant to the applicable provisions of
the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and the rules and regulations promulgated thereunder, we are filing with the Securities and Exchange Commission (the &#147;Commission&#148;), via EDGAR, a Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> relating to the offering of shares of the Company&#146;s common stock (the &#147;Registration Statement&#148;). Marked copies, which reflect changes to the above-referenced Amendment
No.&nbsp;2 to the draft Registration Statement as confidentially submitted on July&nbsp;28, 2021 (&#147;Amendment No.&nbsp;2&#148;), are being furnished supplementally for the convenience of the staff of the Commission (the &#147;Staff&#148;). The
Registration Statement has been revised in response to the comment letter to Jennifer Buell, Ph.D., President, Chief Executive Officer and Director of the Company, dated August&nbsp;12, 2021, from the Staff regarding Amendment No.&nbsp;2, as well as
certain other updated information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For reference purposes, the comment contained in the Staff&#146;s letter dated August&nbsp;12, 2021 is
reproduced below in italics and the corresponding response is shown below the comment. All references to page numbers in the Company&#146;s response are to the page numbers in the Registration Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securities and Exchange Commission</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">- 2 -</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">September&nbsp;13, 2021</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Key Features of iNKT Cells </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Naturally Suited for Allogeneic Approaches, page 83 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
<I>We note your disclosure that &#147;[i]n both clinical and preclinical studies, iNKT cells have been observed not to cause, but instead to actively suppress, GvHD, lowering the safety risks associated with other allogeneic immune cells.&#148; With
reference to your disclosure on page 14, please revise the disclosure on page 83 to provide context to these observations by explaining, if true, that no allogeneic iNKT cell therapy has been deemed safe or been approved by FDA or by any comparable
regulatory authority.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Response to Comment 1: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the Staff&#146;s comment, the Company has revised page 83 of the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securities and Exchange Commission</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">- 3 -</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">September&nbsp;13, 2021</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hope that the foregoing has been responsive to the Staff&#146;s comments. If you have any
questions about this letter or require any further information, please call the undersigned at (617) <FONT STYLE="white-space:nowrap">951-7663</FONT> or Thomas J. Danielski of our offices at (617) <FONT STYLE="white-space:nowrap">235-4961.</FONT>
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Zachary R. Blume</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Zachary R. Blume</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Garo Armen (MiNK Therapeutics, Inc.) </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Jennifer S. Buell (MiNK Therapeutics, Inc.) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Thomas J. Danielski (Ropes&nbsp;&amp; Gray LLP) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g111280dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280dsp01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !/ #\# 2(  A$! Q$!_\0
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M^VOB%^T[XUT__@@S-\5(=8FB\>2?"N'5?[548E6\DLTW3CT?<Q8'LW-> _\
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M9'Q!T[XK?\&_/B?Q)I&C0>'=+UOX60W=KI4'^JTV-[:(K G^R@^4>P%>)?\
M!/[_ )5F?&7_ &+/BK_T.ZKT#XG_ /*LF_\ V1RT_P#22*NG$2<JVO2H<>$@
MH4/=ZTKO^OF8G_!43_E ;\._^O/P3_Z,LJ[G_@OY876J_LI?"JUL;Y]+O;GX
MK^&X;:]2)96LY6>4)*$;Y6*,0VT\'&#7#?\ !43_ )0&_#O_ *\_!/\ Z,LJ
M]%_X+L_\FY_!O_LL'A;_ -'25G1^.G_CG_[::UM855_<A_[<=W\+?^":.K0_
MM-^&/BM\5_C%XK^+OB'P)!<1>&;6[TRTTG3](>X39+,(;=0'E*<;B?3@X&/
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MK6^E]^OYW,:V"A4^.3Z)[>]9W5]//I8^9]?T5]=^(OBS]E6WMY!X@\0?&_\
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MTTJE3@_**<MA4]UZ6/$_AK_RK22_]B!?_P#H^:M?]N'_ )1X?LJ_]C7X)_\
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A5_9,URVU"W-M._CG7IE0NKY1KLE3E21R/QH?4(=/F?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
